Kindred Biosciences, Inc. (KIN)
(Delayed Data from NSDQ)
$9.16 USD
+0.33 (3.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $9.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[KIN]
Reports for Purchase
Showing records 1 - 20 ( 63 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
KindredBio Announces Buyout Agreement; Downgrade to Neutral with $9.25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Continued Progress in Parvovirus and Dermatitis Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Expected Approval of KIND-030 by YE21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Pipeline Development on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Elanco Partnership Provides Further Validation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Second KIND-030 Pivotal Readout by Year End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Positive Prophylactic Pivotal Efficacy Data for KIND-030; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Streamline Operations to Cater to Strategic Shift; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Multiple Clinical Catalysts in View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Committing to a Lower Risk Business Model; Adjust PT to $9.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Technology Development to Bolster Canine Biologics Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Canine AD Development Franchise Strengthened; Two Approvals Pocketed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Two Approvals Expected by YE; Adjust PT to $16.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
NCI Contract Validates cGMP Biologicals Manufacturing Expertise; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Mirataz Sales Back on Track; Catalyst-rich 2H19; Reiterate Buy; Adjust PT to $17.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Positive Top-Line Results From KIND-016 Pilot Study; Pivotal Study to Start in 2H19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Biomedical and Genetics
Online gaming sector - Diversification and scale for online success
Provider: Edison Investment Research Limited
Industry: Medical - Biomedical and Genetics
Tepid Mirataz Sales; But Too Early to Be Disappointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S